Caring Ambassadors Hepatitis C
Program Newsletter
www.HepCChallenge.org
January 2011
Clinical Trials, Cohort Studies, Pilot Studies
Integrated internist - addiction
medicine - hepatology model for hepatitis C management for individuals on
methadone maintenance. Martinez
AD, Dimova R, Marks KM, et al. J Viral Hepat. 2010 Dec 3. doi:
10.1111/j.1365-2893.2010.01411.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21129131
Hepatitis C virus-related kidney
disease: various histological patterns. Sumida K, Ubara Y, Hoshino J, et al. Clin Nephrol.
2010 Dec;74(6):446-56.
http://www.ncbi.nlm.nih.gov/pubmed/21084048
Early Menopause is Associated
with Lack of Response to Antiviral Therapy in Women with Chronic Hepatitis C. Villa E, Karampatou A, Cammà C, et
al. Gastroenterology. 2010 Dec 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21167831
Increasing Prevalence of HCC and
Cirrhosis in Patients with Chronic Hepatitis C Virus Infection. Kanwal F, Hoang T, Kramer JR, et
al. Gastroenterology. 2010 Dec 21. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21184757
Hepatitis C virus and alcohol:
Same mitotic targets but different signaling pathways.
Alisi A, Ghidinelli M, Zerbini A,
Missale G, Balsano C. J Hepatol. 2010 Dec 21. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21145809
Indications and limitations for
aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus
ribavirin combination therapy.
Oze T, Hiramatsu N, Yakushijin T,
et al. J Hepatol. 2010 Dec 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21145907
The Effects of Angiotensin
Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial
Cohort. Abu
Dayyeh BK, Yang M, Dienstag JL, Chung RT. Dig Dis Sci. 2010 Dec 7. [Epub ahead
of print]
http://www.ncbi.nlm.nih.gov/pubmed/21136163
Glucose control and lipid
metabolism in African American patients with type 2 diabetes and chronic
hepatitis C. Zambare
S, Samantray J, Seyoum B, Abou-Samra AB. Endocr Pract. 2010 Dec 6:1-19. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21134881
Neutralizing antibodies to
interferon-α and circulating interferon in patients with chronic hepatitis
C non-responding to pegylated interferon plus ribavirin re-treated by pegylated
interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Halfon P, Pérusat S, Bourlière M,
et al. J Med Virol. 2010 Dec;82(12):2027-31.
http://www.ncbi.nlm.nih.gov/pubmed/20981789
Hepatitis C virus infection and
increased risk of cerebrovascular disease. Lee MH, Yang HI, Wang CH, et al. Stroke. 2010
Dec;41(12):2894-900. Epub 2010 Oct 21.
http://www.ncbi.nlm.nih.gov/pubmed/20966408
Development and Progression of
Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C. Fontana RJ, Sanyal AJ, Ghany MG, et
al. Am J Gastroenterol. 2010 Dec 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21139575
Early proteomic analysis may
allow noninvasive identification of hepatitis C response to treatment with
pegylated interferon α-2b and ribavirin. Devitt EJ, Power KA, Lawless MW, et
al. Eur J Gastroenterol Hepatol. 2010 Dec 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21164346
Effects of multiple-dose pegylated interferon alfa-2b on
the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Gupta SK, Kolz K, Cutler DL. Eur J Clin Pharmacol. 2010 Dec 16. [Epub
ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21161196
A comparison of the natural
history and outcome of treatment for Asian and non-Asian hepatitis C-infected
patients. Lawson
A; on behalf of the Trent Hepatitis C Study Group. J Viral Hepat. 2010 Dec 7.
doi: 10.1111/j.1365-2893.2010.01406.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21138506
Basic and Applied Science, Pre-Clinical Studies
Dynamic coinfection with multiple
viral subtypes in acute hepatitis C. Smith
JA, Aberle JH, Fleming VM, et al. J Infect Dis. 2010 Dec 15;202(12):1770-9.
Epub 2010 Nov 10.
http://www.ncbi.nlm.nih.gov/pubmed/21067369
Reactivation of Epstein-Barr
virus in B cells of patients with chronic hepatitis C.
Shimozuma Y, Ito T, Inokuchi M,
Uchikoshi M, et al. J Med Virol. 2010 Dec;82(12):2064-72.
http://www.ncbi.nlm.nih.gov/pubmed/20981794
Interferon-α suppressed
granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8
agonist. Tajuddin
T, Ryan EJ, Norris S, Hegarty JE, O'Farrelly C. J Gastroenterol Hepatol. 2010
Dec;25(12):1883-90. doi: 10.1111/j.1440-1746.2010.06281.x.
http://www.ncbi.nlm.nih.gov/pubmed/21092001
Characterization of the specific
CD4+ T cell response against the F protein during chronic hepatitis C virus
infection. Gao
DY, Jin GD, Yao BL, et al. PLoS One. 2010 Dec 6;5(12):e14237.
http://www.ncbi.nlm.nih.gov/pubmed/21151917
Coinfection
Changing Rate of Non-B Subtypes and Coinfection with Hepatitis B/C Viruses in Newly Diagnosed HIV Type 1 Individuals in Spain. Treviño A, Soriano V, Rodríguez C, et al. AIDS Res Hum Retroviruses. 2010 Dec 6. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21039316
Treatment for hepatitis C virus
genotype 1 infection in HIV-infected individuals on metha-done maintenance
therapy. Taylor
LE, Bowman SE, Chapman S, et al.
http://www.ncbi.nlm.nih.gov/pubmed/21177046
Chronic immune activation in the
T cell compartment of HCV/HIV-1 co-infected patients.
Sandberg JK, Falconer K, Gonzalez
VD. Virulence. 2010 Dec 22;1(3):177-9.
http://www.ncbi.nlm.nih.gov/pubmed/21178437
Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning. Cohen RA, de la Monte S, Gongvatana A, et al. J Neuroimmunol. 2010 Dec 9. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21146232
Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B poly-morphism in HIV/HCV co-infected patients. de Araújo ES, Dahari H, Cotler SJ, et al. J Acquir Immune Defic Syndr. 2010 Dec 13. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21157362
Incidence and risk factors for
steatosis progression in adults coinfected with HIV and hepatitis C virus. Woreta TA, Sutcliffe CG, Mehta
SH, et al. Gastroenterology. 2010 Dec 3. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21134375
Acute hepatitis C in HIV-infected
individuals - recommendations from the NEAT consensus conference. Rockstroh JK; The European AIDS
Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. AIDS. 2010
Dec 6. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21139491
Predicting spontaneous clearance
of acute hepatitis C virus in a large cohort of HIV-1-infected men. Thomson EC, Fleming VM, Main J, et
al. Gut. 2010 Dec 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21139063
Impact of liver steatosis on the
correlation between liver stiffness and fibrosis measured by transient
elastography in patients coinfected with human immunodeficiency virus and
hepatitis C virus. Sánchez-Conde
M, Montes Ramírez ML, Bellón Cano JM, et al. J Viral Hepat. 2010 Dec 3. doi:
10.1111/j.1365-2893.2010.01407.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21129129
Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Taylor LE, Bowman SE, Chapman S, et al. Drug Alcohol Depend. 2010 Dec 20. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21177046
An Interrupted Time Series
Evaluation of a Hepatitis C Intervention for Persons with HIV.
Proeschold-Bell RJ, Hoeppner B,
Taylor B, Cohen S, Blouin R, Stringfield B, Muir AJ. AIDS Behav. 2010 Dec 30.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21191643
Complementary and Alternative Medicine
Vitamin D deficiency and a
CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and
poor response to interferon-alfa based therapy. Lange CM, Bojunga J, Ramos-Lopez
E, et al. J Hepatol. 2010 Dec 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21145801
Vitamins B status and
antioxidative defense in patients with chronic hepatitis B or hepatitis C virus
infection. Lin
CC, Liu WH, Wang ZH, Yin MC. Eur J Nutr. 2010 Dec 24. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21184088
Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: A meta-analysis of randomised trials. Zhao S, Liu E, Wei K, et al. Antiviral Res. 2010 Dec 15. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21167210
Association Of Caffeine Intake
and Histological Features of Chronic Hepatitis C. Costentin CE, Roudot-Thoraval F,
Zafrani ES, et al. J Hepatol. 2010 Dec 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21145804
Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection. White DL, Richardson PA, Al-Saadi M, et al. Dig Dis Sci. 2010 Dec 28. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21188525
Epidemiology, Diagnostics, and Miscellaneous Works
Injection practices among
clinicians in United States health care settings. Pugliese G, Gosnell C, Bartley
JM, Robinson S. Am J Infect Control. 2010 Dec;38(10):789-98.
http://www.ncbi.nlm.nih.gov/pubmed/21093696
Evaluation of a New; Rapid Test
for Detecting HCV Infection; Suitable for Use with Blood or Oral Fluid. Lee SR, Kardos KW, Schiff E, et
al. J Virol Methods. 2010 Dec 20. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21182871
Infectious disease comorbidities
adversely affecting substance users with HIV: hepatitis C and tuberculosis. Friedland G. J Acquir Immune
Defic Syndr. 2010 Dec 1;55 Suppl 1:S37-42.
http://www.ncbi.nlm.nih.gov/pubmed/21045598
Barriers to and facilitators of
hepatitis C testing, management, and treatment among current and former
injecting drug users: a qualitative exploration. Swan D, Long J, Carr O, et al. AIDS
Patient Care STDS. 2010 Dec;24(12):753-62.
http://www.ncbi.nlm.nih.gov/pubmed/21138381
Effects of recognizing depression
with a standardized questionnaire (CES-D) versus patient reporting of
depression after a single-standardized question on the outcomes of treatment
for hepatitis C with pegylated interferon-α-2b and ribavirin. Phillips FH, Prebis M, Grumbeck
C, Hale T, Cubillas R, Brown GR. Eur J Gastroenterol Hepatol. 2010
Dec;22(12):1435-42.
http://www.ncbi.nlm.nih.gov/pubmed/20802340
Liver Cancer
Increasing Prevalence of HCC and
Cirrhosis in Patients with Chronic Hepatitis C Virus Infection. Kanwal F, Hoang T, Kramer JR, et
al. Gastroenterology. 2010 Dec 21. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21184757
Predictive value of tumor markers
for hepatocarcinogenesis in patients with hepatitis C virus. Kumada T, Toyoda H, Kiriyama S, et
al. Gastroenterol. 2010 Dec 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21132575
Correlation between clinical characteristics, survival and genetic alterations in patients with hepatocellular carcinoma from Saudi Arabia. Al-Qahtani A, Al-Hazzani T, Al-Hussain T, et al. Cancer Genet Cytogenet. 2010 Dec;203(2):269-77.http://www.ncbi.nlm.nih.gov/pubmed/21156243
Effect of pegylated interferon
therapy on intrahepatic recurrence after curative treatment of hepatitis C
virus-related hepatocellular carcinoma.
Hagihara H, Nouso K, Kobayashi Y,et
al. Int J Clin Oncol. 2010 Dec 9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21152943
Hepatitis B and C virus
hepatocarcinogenesis: Lessons learned and future challenges.
Bouchard MJ, Navas-Martin S. Cancer
Lett. 2010 Dec 17. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21168955
Serum level of adiponectin and
the risk of liver cancer development in chronic hepatitis C patients. Arano T, Nakagawa H, Tateishi R, et
al. Int J Cancer. 2010 Dec 17. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21170963